NEWS

Three questions to Prof. Gottfried Baier
1. New immunotherapeutic drugs such as CAR-T cells can benefit patients with certain blood cancers such as leukemia, lymphoma and multiple myeloma. What are the main reasons that the use...
December 18, 2023
Press release: invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma

• Preclinical study will be conducted by Dr. David Reardon’s research group • Immune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer Vienna, Austria and Boston,…

November 10, 2023
Press release: invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding

Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started; invIOs awarded up to 45% funding of trial…

September 5, 2023
invIOs’s EPiC cell therapy platform to progress development of novel CAR-T cell approach against lung cancer with Medical University of Innsbruck
invIOs is teaming up with the Medical University of Innsbruck on a new project to investigate the potential of an innovative CAR-T cell therapy approach to treat aggressive lung tumors....
July 5, 2023
Press release: invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors
INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indications Treatment with INV501 significantly inhibits tumor growth, extends survival and increases cure...
June 16, 2023
Lessons from the clinic: Checkpoint blockade, biomarkers, and the future of individualized solid tumor treatments
We were privileged to welcome Professor Christoph Zielinski as our latest speaker in the invIOs Innovation Lectures. One of Europe's most distinguished medical oncologists, Professor Zielinski shared with us insights...
June 2, 2023
Press release: invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023
APN401 induced prolonged stable disease in two heavily pre-treated patients, using invIOs’s proprietary rapid cell-processing platform technology to manufacture Cbl-b silenced PBMCs and deliver treatment in under 24 hours Data...
April 18, 2023
Meet invIOs’s new Scientific Advisory Board
Today we're unveiling our new Scientific Advisory Board (SAB), which brings together five leading European cancer experts to help fast-forward our growth. The SAB is a multi-disciplinary formation with cross-cutting knowledge...
February 24, 2023
Clinical trials: From bench to bedside to improve outcomes for cancer patients
Clinical trials are crucial to understanding how drugs and therapies work, how safe they are in humans, and how effective they are in treating cancer. They are vital for making...
January 18, 2023
Press release: invIOs to present at Biotech Showcase
Vienna, Austria, 14 December 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that CEO Peter Llewellyn-Davies will present a corporate update during...
December 14, 2022
Three questions to Sarah Bischof, Head of Clinical Operations
1. What are the current main characteristics of clinical trials for cancer treatments? Sarah Bischof: Oncology is a leading area for innovative R&D on many metrics – whether number of...
November 21, 2022
Press release: invIOs presents positive patient data from ongoing Phase 1b trial of APN401 cell therapy in advanced solid tumors at SITC 2022
Poster presentation shows treatment with APN401, an autologous cell therapy product targeting the master immune checkpoint Cbl-b, resulted in stabilization of disease for more than six months in a heavily...
November 9, 2022
Press release: APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01

Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2 Investigators recommend further development of inhaled APN01, which…

November 3, 2022
Press release: invIOs to present data from clinical stage Cbl-b program at SITC 2022

Vienna, Austria, 18 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces that two abstracts on its clinical stage lead program, APN401,…

October 18, 2022
Press release: invIOs to present at upcoming industry and investor conferences
Vienna, Austria, 11 October 2022: invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation at three upcoming industry and investor conferences: BIO-Europe, Inv€$tival...
October 11, 2022
Cancer – the hallmarks and beyond
Although cancer represents a huge challenge for our healthcare systems, new immunotherapies and other advanced novel treatments mean hope is on the horizon. Cancer is one of the all-pervading topics...
September 26, 2022
Three questions to Mario Kuttke, Head of Cell Therapy
1. Do cell therapies represent a breakthrough in cancer treatment? Mario Kuttke: It is really amazing how adoptive cell therapy (ACT), a form of cancer immunotherapy, has evolved so rapidly...
July 27, 2022
The race against cancer – targeting Cbl-b in cellular therapy
invIOs’s novel clinical stage lead therapeutic candidate, APN401, combines advances in immune cell therapy and RNA interference methods to treat advanced solid cancers. Immune therapy – hitting new targets Immune...
June 29, 2022
Press release: APEIRON shareholders approve new group structure
geared towards enabling innovation and growth invIOs becomes fully separate entity focused on advancing its unique EPiC cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 26 April 2022. APEIRON...
April 26, 2022
Three questions to Alexander Dohnal, Head of Preclinical Development
1. Ribonucleic acids have for a long time been DNA’s “little sister”. What’s so different between RNA and DNA? Alexander Dohnal: RNA and DNA have a lot in common. Chemical...
April 5, 2022
RNA – in the midst of a medical revolution

Ribonucleic acid (RNA) therapies are promising to change the way we treat diseases. From cancer therapies to vaccines and treatments for genetic diseases, the opportunities are almost infinite.

April 5, 2022
Press release: invIOs to present at upcoming conferences
Vienna, Austria, 03 February 2022: invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, today announced the participation at three upcoming investor conferences, the BIO CEO &...
February 3, 2022
Unlocking the master checkpoint of cancer immunity

Our knowledge of cancer is growing daily, bringing with it new treatment strategies. As mentioned previously (here) novel immunotherapies are at the forefront of cancer research. The immune activating monoclonal…

January 28, 2022
Three questions to Romana Gugenberger, Chief Medical and Scientific Officer

1.   Despite novel immune-therapies against cancer there are still non-responders and relapses. Why is that? Romana Gugenberger:  Tumors are heterogeneous. Additionally, tumors are not static but evolve. Once a response…

January 28, 2022
Press release: invIOs goes live

invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 16 December 2021: invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for…

December 15, 2021
The immune system’s fight against cancer

Cancer is the second leading cause of death worldwide. Obviously, the complex cancer biology and simultaneous failure of our body to halt the transformation of a normal cell into cancer…

December 15, 2021
Perspectives: The Cancer Revolution

Despite recent advances in the treatment of cancer, the disease remains a leading cause of death by disease worldwide1. It is reported that one in two people will be diagnosed…

December 14, 2021
Press release: APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401

Important development step for promising cell therapy Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors Innovative new manufacturing and treatment process enables…

July 6, 2021
Press release: APEIRON Biologics announces changes to management and supervisory boards

Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO) Prof. Josef Penninger moves from…

June 1, 2021
Reactivated immune cells of cancer patients (APN401) for the treatment of solid tumors
In light of the 21st annual #WorldCancerDay we would like to draw your attention to our work in fighting cancer. We at APEIRON Biologics AG want to make a contribution...
February 3, 2021